Covivio (COV.PA) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
You don't hold COV.PA in your mock portfolio yet.
A PE ratio of 9.76 and EPS of 5.47 suggest Covivio is generating solid earnings relative to its share price, with the market valuing it at a discount to many broader equity markets. However, without clear recent revenue and net income trend data, it is difficult to conclude that earnings quality and growth are strong; the low multiple may reflect structural concerns around the real estate sector, interest rates, or asset valuations. Overall, the valuation looks reasonable to mildly attractive, but the lack of visible growth momentum keeps the stance neutral.
The stock trades at €53.40, modestly below its 200‑day moving average of €54.98, and is down 1.5% over the last month, indicating mild short‑term weakness. Trading slightly under the 200‑day average often signals a neutral‑to‑cautious technical setup rather than a clear breakdown, especially given the relatively small gap. Without RSI data, there is no strong evidence of either overbought or oversold conditions, so the technical picture leans neutral.
Alternative data show softening or stagnant engagement and hiring, which can be an early indicator of cautious management and muted growth initiatives. Monthly web traffic at roughly 17,018 visitors is modest, and job openings have fallen 26.3% month over month, suggesting a slowdown in expansion or increased cost discipline. Social media followings are stable with only marginal growth, pointing to limited brand momentum or marketing push.
Overall, Covivio’s stock setup appears neutral: valuation and earnings per share look reasonable, but technicals are slightly soft and alternative data point to cautious corporate behavior and limited growth momentum. The modest discount to the 200‑day moving average and low PE may appeal to value‑oriented investors, yet the lack of strong positive signals from hiring, traffic, or social engagement tempers a bullish view. On balance, the stock does not currently present a clear upside or downside bias based on the available information.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started